Abstract

Background

There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).

Methods

Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.

Results

We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).

Conclusions

We suggest potential mechanisms to optimize these compounds and their future clinical implementation.

Details

Title
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
First page
1
Section
Review
Publication year
2020
Publication date
2020
Publisher
BioMed Central
ISSN
1465-5411
e-ISSN
1465542X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s13058-020-1252-7
ProQuest document ID
2357641589
Copyright
© 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.